Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 7617-7625

  Jin, Z Y ^a,b   Xu, S F ^a   Zhao, X T ^a   Zhang, L N ^a   Wang, Y ^a   Yue, W T ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY   (China)

Author keywords

NSCLC; SNPs; XPG; XRCC1; XRCC3

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; GENOMIC DNA; NAVELBINE; PACLITAXEL; XRCC1 PROTEIN; XRCC3 PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC-5; ENDONUCLEASE; NUCLEAR PROTEIN; PLATINUM; TRANSCRIPTION FACTOR; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 3;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DNA EXTRACTION; DRUG RESPONSE; FEMALE; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; XPG GENE; XRCC1 GENE; XRCC3 GENE; ALLELE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PLATINUM; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84907147230     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.March.31.13     Document Type: Article

References (22)

1. Carles J, Monzo M, Amat M, Jansa S, et al. (2006). Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 66: 1022-1030.
2. Cheng L, Spitz MR, Hong WK and Wei Q (2000). Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 21: 1527-1530.
3. Cheng L, Sturgis EM, Eicher SA, Spitz MR, et al. (2002). Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 94: 393-397.
4. de Boer J and Hoeijmakers JH (2000). Nucleotide excision repair and human syndromes. Carcinogenesis 21: 453-460.
5. Doherty JA, Weiss NS, Fish S, Fan W, et al. (2011). Polymorphisms in nucleotide excision repair genes and endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev. 20: 1873-1882.
6. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, et al. (2000). Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21: 965-971.
7. Giachino DF, Ghio P, Regazzoni S, Mandrile G, et al. (2007). Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin. Cancer Res. 13: 2876-2881.
8. Grønberg BH, Bremnes RM, Flotten O, Amundsen T, et al. (2009). Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 27: 3217-3224.
9. Gurubhagavatula S, Liu G, Park S, Zhou W, et al. (2004). XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22: 2594-2601.
10. Hussain SK, Mu LN, Cai L, Chang SC, et al. (2009). Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China. Cancer Epidemiol. Biomarkers Prev. 18: 2304-2309.
11. International Agency for Research on Cancer (2008). Lung Cancer Incidence, Mortality and Prevalence Worldwide in 2008. Available at [http://globocan. iarc. fr/factsheet. asp.]. Accessed June 10, 2013.
12. Jeon HS, Kim KM, Park SH, Lee SY, et al. (2003). Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer. Carcinogenesis 24: 1677-1681.
13. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, et al. (2009). DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 10: 118-123.
14. Liao WY, Shih JY, Chang GC, Cheng YK, et al. (2012). Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J. Thorac. Oncol. 7: 973-981.
15. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, et al. (1999). XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 59: 2557-2561.
16. Monaco R, Rosal R, Dolan MA, Pincus MR, et al. (2007). Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J. 26: 541-546.
17. Reed E (1998). Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 24: 331-344.
18. Sun X, Li F, Sun N, Shukui Q, et al. (2009). Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65: 230-236.
19. Tahara E, Yasui W, Ito H and Harris CC (2010). Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities Consortium International Symposium, November 2009. Jpn. J. Clin. Oncol. 40: 702-708.
20. Weaver DA, Crawford EL, Warner KA, Elkhairi F, et al. (2005). ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol. Cancer 4: 18.
21. William WN Jr, Lin HY, Lee JJ, Lippman SM, et al. (2009). Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 136: 701-709.
22. Yao CY, Huang XE, Li C, Shen HB, et al. (2009). Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac. J. Cancer Prev. 10: 859-864.